- Home
- / Quince Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Quince Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.2
2024-10-29
Market Capitalization
$51.1 M
2024-10-29
Revenue
$262 K
FY, 2022
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 262.0K | ||||||||
| General and administrative expense | 1.3M | 2.0M | 9.0M | 17.6M | 29.5M | 26.0M | 17.7M | 17.6M | 15.0M |
| Operating expense total | 10.4M | 12.1M | 39.2M | 78.9M | 52.0M | 36.2M | 50.4M | ||
| Depreciation and amortization | 100.0K | ||||||||
| EBIT | (10.4M) | (12.1M) | (39.2M) | (78.9M) | (90.3M) | (52.0M) | (34.6M) | (57.3M) | (58.1M) |
| EBIT margin, % | -19853.1% | ||||||||
| Investment income | 2.2M | ||||||||
| Interest income | 806.0K | 2.0M | 620.0K | 1.1M | 3.5M | 2.9M | 1.2M | ||
| Interest expense | 1.6M | 957.0K | |||||||
| Pre tax profit | (89.9M) | (51.9M) | (31.6M) | (56.7M) | (80.8M) | ||||
| Income tax expense | (300.0K) | 197.0K | 87.0K | 3.2M | |||||
| Net Income | (12.2M) | (12.5M) | (37.0M) | (76.8M) | (89.9M) | (51.7M) | (31.4M) | (56.8M) | (84.0M) |
| EPS | (1.5) | (1.3) | (1.7) |